Effects of amiloride on physiological activity of stem cells of human lung cancer and possible mechanism

被引:8
作者
Zhang, Hengshuo [1 ]
Peng, Caixia [2 ]
Huang, He [1 ]
Lai, Yongxin [2 ]
Hu, Chenchen [2 ]
Li, Fei [3 ]
Wang, Degui [4 ]
机构
[1] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
[2] Lanzhou Univ, Clin Med Coll 2, Lanzhou 730000, Gansu, Peoples R China
[3] Lanzhou Univ, Sch Basic Med Sci, Inst Pathogen Biol, Lanzhou 730000, Gansu, Peoples R China
[4] Lanzhou Univ, Sch Basic Med Sci, Dept Anat & Histol, Lanzhou 730000, Gansu, Peoples R China
基金
中国国家自然科学基金;
关键词
Lung cancer; Stem cell; Amiloride; NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; MIGRATION; INVASION; APOPTOSIS; INHIBITION; RECEPTOR; UPAR;
D O I
10.1016/j.bbrc.2018.06.138
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lung cancer is a common malignant tumor, the cancer stem cells (CSCs) were regarded responsible for the development of cancer tissue. The effects of amiloride on lung cancer stem cells and the possible mechanism were not much investigated. In this study, human NCI-H1975 lung CSCs were selected by flow cytometry, and the effects of amiloride at different concentrations (0, 12.5, 25, 50, and 100 mu mol/L) were evaluated on proliferation, migration, invasion and apoptosis of CSCs using cell counting kit-8 and Transwell migration assays as well as flow cytometry. Wstern blot analysis was performed to investigate the effect of amiloride on the level of proteins in uPA system, NF-kB pathway, and PI3K-AKT-mTOR pathway in CSCs. As a result, we found that amiloride inhibited proliferation, migration and invasion of lung CSCs, and promoted apoptosis. Further, we found that amiloride decreased levels of target proteins in the uPA system, as well as the NF-kB and PI3K-AICT-mTOR pathways. These results indicated that amiloride could inhibit proliferation, migration and invasion of lung CSCs, and promotes apoptosis, these effects may be related to decreased levels of proteins in the uPA system, the NF-kB pathway, and the PI3K-AKT-mTOR pathway. (C) 2018 Published by Elsevier Inc.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 24 条
[1]   Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen [J].
Bailon, Elvira ;
Ugarte-Berzal, Estefania ;
Amigo-Jimenez, Irene ;
Van den Steen, Philippe ;
Opdenakker, Ghislain ;
Garcia-Marco, Jose A. ;
Garcia-Pardo, Angeles .
JOURNAL OF LEUKOCYTE BIOLOGY, 2014, 96 (02) :185-199
[2]   Amiloride Modulates Alternative Splicing in Leukemic Cells and Resensitizes Bcr-AblT315I Mutant Cells to Imatinib [J].
Chang, Wen-Hsin ;
Liu, Ta-Chih ;
Yang, Wen-Kuang ;
Lee, Chien-Chih ;
Lin, Yi-Hsiung ;
Chen, Tsai-Yun ;
Chang, Jan-Gowth .
CANCER RESEARCH, 2011, 71 (02) :383-392
[3]  
Gond CS, 2007, INT J ONCOL, V31, P19
[4]  
Gu K, 2015, AM J CANCER RES, V5, P1169
[5]   Amiloride kills malignant glioma cells independent of its inhibition of the sodium-hydrogen exchanger [J].
Hegde, M ;
Roscoe, J ;
Cala, P ;
Gorin, F .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (01) :67-74
[6]  
Indira Chandran Vineesh, 2015, Oncoscience, V2, P207
[7]  
JEMAL A, 2011, CA-CANCER J CLIN, V61, P134, DOI [DOI 10.3322/caac.20115, DOI 10.3322/CAAC.20107]
[8]   Reversibility of Epithelial-Mesenchymal Transition (EMT) Induced in Breast Cancer Cells by Activation of Urokinase Receptor-dependent Cell Signaling [J].
Jo, Minji ;
Lester, Robin D. ;
Montel, Valerie ;
Eastman, Boryana ;
Takimoto, Shinako ;
Gonias, Steven L. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (34) :22825-22833
[9]   uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells [J].
Lester, Robin D. ;
Jo, Minji ;
Montel, Valerie ;
Takimoto, Shinako ;
Gonias, Steven L. .
JOURNAL OF CELL BIOLOGY, 2007, 178 (03) :425-436
[10]   Quercetin Has Antimetastatic Effects on Gastric Cancer Cells via the Interruption of uPA/uPAR Function by Modulating NF-b, PKC-, ERK1/2, and AMPK [J].
Li, Hai ;
Chen, Chen .
INTEGRATIVE CANCER THERAPIES, 2018, 17 (02) :511-523